RNL Bio offers hope for liver patients by stem cell therapy

Jan. 28, 2009 - PRLog -- RNL Bio Co., Ltd, a leading biopharmaceutical company specialized in adult stem cell based therapeutics, announced on Jan 21 that its fat derived stem cell therapy showed effect on the restoration of liver function when they were intravenously delivered to patients.
Patients with liver disease were treated by adipose tissue derived stem cells at RNL ChoYang Center for Stem Cell and Regenerative Medicine (RNL CSCRM) which was established last November in Yanji, China. Liver function was significantly restored when liver damage patients were treated with stem cells by intravenous infusion
RNL CSCRM offers adult stem cell therapy using local and intravenous delivery to repair diseases associated with cellular damage and resulted from aging. This stem cell therapeutics has boomed among patients from China, Japan, Korea and other countries with hope for cellular regeneration and anti-aging purpose.
At RNL CSCRM, fat from patients is isolated and expanded up to a few hundreds million cells. Intravenous delivery of those autologous stem cells is an epochal procedure that is painless and non-invasive.
Physicians monitored patients’ liver function pro and post stem cell treatments They confirmed significant improvement in liver function test results and measurements, such as ALT ALP and γGTP were mostly restored back to normal.
A representative from RNL Bio said ‘Patients with liver diseases are now given hope by our new stem cell treatment offered at our clinic in China where treatments using patients’ own stem cells are allowed. We are very glad to bring good news to those patients through our stem cell therapeutics that was developed and already brought to human trials in Korea’.
As the prevalence of chronic HBV infection in areas of high endemicity is at least 8% in China and Africa and liver disease is fifth largest cause of death in South Korea, this new treatment is expected to greatly contribute to the public health of those countries.

# # #

RNL Bio has developed technologies for stem cells therapeutics and natural product screening with the mission to extend and ensure the quality of live for all mankind. RNL has operated state of the art family stem cell bank, named Biostar. RNL focuses on the commercialization of stem cell therapeutics for the treatment of diabetes, spinal cord injury, incontinence of urine, Beurger’s disease and osteoarthritis. RNL is a publicly traded company on the Korean Stock Exchange (Code 003190)